| Schedule of revenue and expenses for the operating segment to consolidated amounts |
| | | | | | | | | | | | | | | Three months ended September 30, | | Nine months ended September 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Operating expenses: | | | | | | | | | | | | | Contracted research expense | | $ | 14,989 | | $ | 22,623 | | $ | 66,770 | | $ | 62,939 | Personnel expense | | | 13,285 | | | 11,079 | | | 43,827 | | | 32,596 | Stock-based compensation expense | | | 8,565 | | | 8,085 | | | 26,641 | | | 24,877 | Other segment expense(a) | | | 8,774 | | | 4,548 | | | 23,355 | | | 13,456 | Depreciation | | | 530 | | | 523 | | | 1,608 | | | 1,559 | Segment net income (loss) | | | (46,143) | | | (46,858) | | | (162,201) | | | (135,427) | | | | | | | | | | | | | | Reconciliation of net income (loss) | | | | | | | | | | | | | Interest income | | | 16,496 | | | 6,192 | | | 26,214 | | | 17,848 | Other income | | | 3,065 | | | — | | | 3,065 | | | — | Gain on the Sevasemten Sale | | | 1,348,066 | | | — | | | 1,348,066 | | | — | Income tax expense | | | 155,333 | | | — | | | 155,333 | | | — | Net income (loss) | | $ | 1,166,151 | | $ | (40,666) | | $ | 1,059,811 | | $ | (117,579) |
a Other segment expense included in Segment net income (loss) includes contracted administrative expenses, intellectual property fees, software costs, occupancy & equipment costs, and other overhead expenses.
|